Your session is about to expire
← Back to Search
Angioplasty Device
Serranator for Peripheral Arterial Disease
N/A
Recruiting
Research Sponsored by Cagent Vascular LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 minutes post procedure
Awards & highlights
Study Summary
The study objective is to assess the ability to define and measure post treatment recoil in infrapopliteal arteries. Preliminary evidence as to the differences between serration angioplasty and standard balloon angioplasty as defined by post treatment recoil, lumen gain, and dissection will be collected.
Eligible Conditions
- Peripheral Arterial Disease
- Critical Limb Ischemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 minutes post procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 minutes post procedure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Presence of post treatment recoil
Trial Design
2Treatment groups
Experimental Treatment
Group I: SerranatorExperimental Treatment1 Intervention
Group II: POBAExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Serranator
2019
N/A
~50
POBA
2016
Completed Phase 4
~1750
Find a Location
Who is running the clinical trial?
Cagent Vascular LLCLead Sponsor
3 Previous Clinical Trials
74 Total Patients Enrolled
3 Trials studying Peripheral Arterial Disease
74 Patients Enrolled for Peripheral Arterial Disease
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger